Levofloxacin and trovafloxacin inhibition of experimental fracture-healing

Archie C. Perry, Branko Prpa, Mark S. Rouse, Kerryl E. Piper, Arlen D. Hanssen, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

We previously have shown that experimental fractures exposed to ciprofloxacin have diminished fracture healing. The purpose of this study was to assess the effect of levofloxacin and trovafloxacin on experimental fracture healing to test the hypothesis that diminished fracture healing is a quinolone class effect. Sixty-one male Wistar rats were divided into three groups, which received 25 mg/kg of levofloxacin twice daily for 3 weeks, 35 mg/kg of trovafloxacin twice daily for 3 weeks, or no treatment, beginning 7 days after production of closed, nondisplaced, bilateral femoral fractures. The mean peak serum concentrations of levofloxacin and trovafloxacin drawn 30 minutes after administration were 6.9 and 7.0 μg/mL, respectively. Radiographic, histologic, and biomechanical studies were used to evaluate fracture healing. Torsional strength testing of fracture callus exposed to levofloxacin and trovafloxacin revealed a decrease in strength (299 and 257 N-mm, respectively) as compared with controls (364 N-mm). Radiographs revealed significantly more advanced healing in control animals (Goldberg score of 2.1) compared with the fractures in the rats treated with levofloxacin and trovafloxacin (Goldberg score of 1.5 in both groups). Fracture calluses in the animals treated with levofloxacin and trovafloxacin showed a lower histologic grade (5.3 and 3.5, respectively) as compared with control animals (7.5) representing a less mature callus with the presence of more cartilage and less woven bone. These data suggest that experimental fractures systemically exposed to levofloxacin or trovafloxacin have diminished healing during the early stages of fracture repair. The administration of quinolones during early fracture repair may compromise fracture healing in humans.

Original languageEnglish (US)
Pages (from-to)95-100
Number of pages6
JournalClinical Orthopaedics and Related Research
Issue number414
StatePublished - Sep 1 2003

Fingerprint

Levofloxacin
Fracture Healing
Bony Callus
Quinolones
Femoral Fractures
Ciprofloxacin
trovafloxacin
Cartilage
Wistar Rats
Bone and Bones
Serum

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Perry, A. C., Prpa, B., Rouse, M. S., Piper, K. E., Hanssen, A. D., Steckelberg, J. M., & Patel, R. (2003). Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clinical Orthopaedics and Related Research, (414), 95-100.

Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. / Perry, Archie C.; Prpa, Branko; Rouse, Mark S.; Piper, Kerryl E.; Hanssen, Arlen D.; Steckelberg, James M.; Patel, Robin.

In: Clinical Orthopaedics and Related Research, No. 414, 01.09.2003, p. 95-100.

Research output: Contribution to journalArticle

Perry, AC, Prpa, B, Rouse, MS, Piper, KE, Hanssen, AD, Steckelberg, JM & Patel, R 2003, 'Levofloxacin and trovafloxacin inhibition of experimental fracture-healing', Clinical Orthopaedics and Related Research, no. 414, pp. 95-100.
Perry AC, Prpa B, Rouse MS, Piper KE, Hanssen AD, Steckelberg JM et al. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clinical Orthopaedics and Related Research. 2003 Sep 1;(414):95-100.
Perry, Archie C. ; Prpa, Branko ; Rouse, Mark S. ; Piper, Kerryl E. ; Hanssen, Arlen D. ; Steckelberg, James M. ; Patel, Robin. / Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. In: Clinical Orthopaedics and Related Research. 2003 ; No. 414. pp. 95-100.
@article{0105915841904a829fce3d201a02293c,
title = "Levofloxacin and trovafloxacin inhibition of experimental fracture-healing",
abstract = "We previously have shown that experimental fractures exposed to ciprofloxacin have diminished fracture healing. The purpose of this study was to assess the effect of levofloxacin and trovafloxacin on experimental fracture healing to test the hypothesis that diminished fracture healing is a quinolone class effect. Sixty-one male Wistar rats were divided into three groups, which received 25 mg/kg of levofloxacin twice daily for 3 weeks, 35 mg/kg of trovafloxacin twice daily for 3 weeks, or no treatment, beginning 7 days after production of closed, nondisplaced, bilateral femoral fractures. The mean peak serum concentrations of levofloxacin and trovafloxacin drawn 30 minutes after administration were 6.9 and 7.0 μg/mL, respectively. Radiographic, histologic, and biomechanical studies were used to evaluate fracture healing. Torsional strength testing of fracture callus exposed to levofloxacin and trovafloxacin revealed a decrease in strength (299 and 257 N-mm, respectively) as compared with controls (364 N-mm). Radiographs revealed significantly more advanced healing in control animals (Goldberg score of 2.1) compared with the fractures in the rats treated with levofloxacin and trovafloxacin (Goldberg score of 1.5 in both groups). Fracture calluses in the animals treated with levofloxacin and trovafloxacin showed a lower histologic grade (5.3 and 3.5, respectively) as compared with control animals (7.5) representing a less mature callus with the presence of more cartilage and less woven bone. These data suggest that experimental fractures systemically exposed to levofloxacin or trovafloxacin have diminished healing during the early stages of fracture repair. The administration of quinolones during early fracture repair may compromise fracture healing in humans.",
author = "Perry, {Archie C.} and Branko Prpa and Rouse, {Mark S.} and Piper, {Kerryl E.} and Hanssen, {Arlen D.} and Steckelberg, {James M.} and Robin Patel",
year = "2003",
month = "9",
day = "1",
language = "English (US)",
pages = "95--100",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "414",

}

TY - JOUR

T1 - Levofloxacin and trovafloxacin inhibition of experimental fracture-healing

AU - Perry, Archie C.

AU - Prpa, Branko

AU - Rouse, Mark S.

AU - Piper, Kerryl E.

AU - Hanssen, Arlen D.

AU - Steckelberg, James M.

AU - Patel, Robin

PY - 2003/9/1

Y1 - 2003/9/1

N2 - We previously have shown that experimental fractures exposed to ciprofloxacin have diminished fracture healing. The purpose of this study was to assess the effect of levofloxacin and trovafloxacin on experimental fracture healing to test the hypothesis that diminished fracture healing is a quinolone class effect. Sixty-one male Wistar rats were divided into three groups, which received 25 mg/kg of levofloxacin twice daily for 3 weeks, 35 mg/kg of trovafloxacin twice daily for 3 weeks, or no treatment, beginning 7 days after production of closed, nondisplaced, bilateral femoral fractures. The mean peak serum concentrations of levofloxacin and trovafloxacin drawn 30 minutes after administration were 6.9 and 7.0 μg/mL, respectively. Radiographic, histologic, and biomechanical studies were used to evaluate fracture healing. Torsional strength testing of fracture callus exposed to levofloxacin and trovafloxacin revealed a decrease in strength (299 and 257 N-mm, respectively) as compared with controls (364 N-mm). Radiographs revealed significantly more advanced healing in control animals (Goldberg score of 2.1) compared with the fractures in the rats treated with levofloxacin and trovafloxacin (Goldberg score of 1.5 in both groups). Fracture calluses in the animals treated with levofloxacin and trovafloxacin showed a lower histologic grade (5.3 and 3.5, respectively) as compared with control animals (7.5) representing a less mature callus with the presence of more cartilage and less woven bone. These data suggest that experimental fractures systemically exposed to levofloxacin or trovafloxacin have diminished healing during the early stages of fracture repair. The administration of quinolones during early fracture repair may compromise fracture healing in humans.

AB - We previously have shown that experimental fractures exposed to ciprofloxacin have diminished fracture healing. The purpose of this study was to assess the effect of levofloxacin and trovafloxacin on experimental fracture healing to test the hypothesis that diminished fracture healing is a quinolone class effect. Sixty-one male Wistar rats were divided into three groups, which received 25 mg/kg of levofloxacin twice daily for 3 weeks, 35 mg/kg of trovafloxacin twice daily for 3 weeks, or no treatment, beginning 7 days after production of closed, nondisplaced, bilateral femoral fractures. The mean peak serum concentrations of levofloxacin and trovafloxacin drawn 30 minutes after administration were 6.9 and 7.0 μg/mL, respectively. Radiographic, histologic, and biomechanical studies were used to evaluate fracture healing. Torsional strength testing of fracture callus exposed to levofloxacin and trovafloxacin revealed a decrease in strength (299 and 257 N-mm, respectively) as compared with controls (364 N-mm). Radiographs revealed significantly more advanced healing in control animals (Goldberg score of 2.1) compared with the fractures in the rats treated with levofloxacin and trovafloxacin (Goldberg score of 1.5 in both groups). Fracture calluses in the animals treated with levofloxacin and trovafloxacin showed a lower histologic grade (5.3 and 3.5, respectively) as compared with control animals (7.5) representing a less mature callus with the presence of more cartilage and less woven bone. These data suggest that experimental fractures systemically exposed to levofloxacin or trovafloxacin have diminished healing during the early stages of fracture repair. The administration of quinolones during early fracture repair may compromise fracture healing in humans.

UR - http://www.scopus.com/inward/record.url?scp=0041317231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041317231&partnerID=8YFLogxK

M3 - Article

SP - 95

EP - 100

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 414

ER -